Loss of cell-cycle control is a hallmark of human cancer. Cell-cycle checkpoints are essential for maintaining genome integrity and balanced growth and division. They are specifically deregulated in cancer cells and contain regulators that represent potential therapeutic targets. Monopolar spindle 1 (Mps1; also known as TTK protein kinase) is a core component of the spindle assembly checkpoint (SAC), a genome-surveillance mechanism that is important for cell survival, and has emerged as a candidate target for anticancer therapy. Here, we report the cellular and antitumor effects of CFI-402257, a potent (Mps1 K i = 0.09 ± 0.02 nM; cellular Mps1 EC 50 = 6.5 ± 0.5 nM), highly selective, and orally active small-molecule inhibitor of Mps1 that was identified through a drug-discovery program. Human cancer cells treated with CFI-402257 exhibit effects consistent with Mps1 kinase inhibition, specifically SAC inactivation, leading to chromosome missegregation, aneuploidy, and ultimately cell death. Oral administration of CFI-402257 in monotherapy or in combination with an anti-programmed cell death 1 (PD-1) antibody in mouse models of human cancer results in inhibition of tumor growth at doses that are well-tolerated. Our findings provide a rationale for the clinical evaluation of CFI-402257 in patients with solid tumors.
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Mps1/TTK | inhibitor | CFI-402257 | cancer M ammalian cell division is tightly regulated by the activation and inactivation of proteins that regulate progression through the phases of the cell cycle. To ensure that only healthy cells proliferate, cell-cycle checkpoints have evolved that play key roles in genome maintenance under various stress conditions and even during an unperturbed cell cycle. These checkpoints are specifically deregulated in cancer cells, and contain regulators that represent potential targets for the design of cancer cell-selective therapies (1) .
The spindle assembly checkpoint (SAC; also known as the mitotic checkpoint) is a signaling cascade that prevents chromosome missegregation by arresting the cell cycle in mitosis until all chromosomes are properly attached to the mitotic spindle (2) . This arrest is achieved by inhibiting the anaphase-promoting complex/ cyclosome (APC/C), an E3 ubiquitin ligase that is essential for mitotic progression. Normal cells have a robust SAC in which one or more unattached chromosomes can produce a signal strong enough to inhibit all cellular APC/C activity and thereby block progression to anaphase. By contrast, many cancer cells have a weakened, but not absent, SAC response that may cause aneuploidy and drive malignancy. However, more severe disabling of SAC checkpoint signaling generates a level of chromosome instability that exceeds the adaption capacity of cancer cells and is a potential anticancer strategy. Of note, nontransformed cells appear to be less sensitive than cancer cells to death caused by SAC inhibition (3, 4) . The core SAC kinase, monopolar spindle 1 (Mps1; also known as TTK protein kinase), is a candidate target for this approach.
Mps1 is an essential, dual-specificity kinase (5) that functions as an important guardian of the fidelity of chromosome segregation. It is critical for the recruitment of SAC proteins to unattached kinetochores, mitotic checkpoint complex formation, and thus APC/C inhibition. Mps1 is also required for chromosome alignment and error correction (6) (7) (8) . Inhibition of Mps1 activity causes cells to prematurely exit mitosis with unattached chromosomes, resulting in severe chromosome missegregation, aneuploidy, and ultimately cell death (4, (9) (10) (11) (12) . Mps1 is expressed during mitosis in proliferating cells. Overexpression of Mps1 is observed in several human tumors, and correlates with worse prognosis (13) (14) (15) (16) (17) (18) (19) . Further, Mps1 has been implicated in facilitating an aneuploidytolerant state in cancer cells (13) . Together, these findings pointed to Mps1 as a rational drug target for anticancer therapy.
We describe here the cellular and antitumor effects of CFI-402257, a potent and selective Mps1 kinase inhibitor. CFI-402257 shows strong antineoplastic activity on a broad panel of human cancer-derived cell lines, and causes effects consistent with depletion or inhibition of Mps1 (4, (9) (10) (11) (12) . Oral administration of CFI-402257 as a single agent to mice bearing human cancer xenografts results in inhibition of tumor growth at doses that are well-tolerated. Notably, the combination of CFI-402257 and an anti-programmed cell death 1 (PD-1) antibody causes tumor regression and increases survival in a murine colon cancer model that mimics the human disease, suggesting that this might be a clinically viable approach.
Results

CFI-402257
Is a Selective Inhibitor of Mps1. Mps1 was identified as a potential therapeutic target through a systematic approach that combined RNAi screening with gene-expression analysis in human breast cancers and cell lines, which previously yielded pololike kinase 4 as an anticancer drug target (20) . Reduction of Significance At present, microtubule-targeting agents are the most important antimitotic drugs used in the clinic. However, there is an urgent need for the discovery of new approaches to more effectively target tumor cells with less toxicity. Emerging strategies for anticancer therapy include exploiting cell-cycle checkpoint vulnerabilities and genomic instability in cancer cells. The spindle assembly checkpoint (SAC) is important for cell survival, and its inactivation generates lethal genomic instability in cancer cells. Inhibition of SAC signaling through targeting of monopolar spindle 1 (Mps1) has provided an indication of the feasibility of such an approach. We report here the cellular and antitumor effects of CFI-402257, a potent and specific small-molecule inhibitor of Mps1. CFI-402257 is currently in a phase I clinical trial (ClinicalTrials.gov ID: NCT02792465).
Mps1 resulted in a loss of cell viability in 8 of 14 cell lines (Fig. S1) , and Mps1 mRNA was found to be overexpressed in 38% of all breast tumors and in 85% of triple-negative/basal-like (TNBC) tumors (Fig.  S2A ) (21) , the subtype considered to be the most genomically unstable class of breast cancer (22) . Of note, reduction of Mps1 inhibited the cell viability of all four basal breast cancer cell lines and both immortalized basal breast cell lines examined. Immunoblot analysis was used to compare Mps1 levels in breast cancer cell lines to those in primary human mammary epithelial cells derived from normal breast tissue samples. Mps1 levels were found to be significantly higher in breast cancer cells relative to their normal tissue counterparts and in basal breast cancer cell lines relative to luminal breast cancer cell lines (Fig. S2B) .
On the basis of these studies, we initiated a drug discovery program that culminated in the discovery of CFI-402257 as a potent and selective small-molecule inhibitor of Mps1 (Fig. 1A ) (23) . In an assay using recombinant human Mps1, CFI-402257 inhibited Mps1 with an IC 50 value of 1.2 ± 0.4 nM, and was ATP competitive with a K i value of 0.09 ± 0.02 nM. Consistent with these results, CFI-402257 inhibited autophosphorylation of Mps1 at threonine 12/serine 15 with an EC 50 value of 6.5 ± 0.5 nM in cells exogenously expressing human Mps1 (Fig. 1B) . Mps1 threonine 12/serine 15 autophosphorylation occurs as a consequence of kinase activation, and thus enables identification of active Mps1 in cells (24) . Immunoblotting of endogenous phosphorylated Mps1 in cell lysates was technically challenging; therefore, cells exogenously expressing Mps1 were used to determine the EC 50 value for inhibition of Mps1 autophosphorylation by CFI-402257.
To evaluate selectivity, CFI-402257 was profiled against a panel of 265 recombinant protein and lipid kinases and a panel of 98 nonkinase targets, including G protein-coupled receptors, nuclear receptors, membrane channels, and enzymes. Of the 265 kinases tested, none showed >50% inhibition when incubated with 1 μM CFI-402257, and no significant inhibitory activity was observed against Aurora kinase, Polo-like kinase, or Cyclin-dependent kinase family members. Only 3 of 98 nonkinase targets were inhibited ≥50% with 10 μM CFI-402257 (Table S1 ). Overall, these results indicate that CFI-402257 selectively and potently inhibits Mps1 kinase activity in cells with minimal off-target effects.
Cellular Effects of CFI-402257. Mps1 contributes to the alignment of chromosomes on the metaphase plate, and is a core component of the SAC, a surveillance mechanism that ensures mitotic fidelity and genome stability. Depletion or inhibition of Mps1 causes cells to exit mitosis with unattached chromosomes, resulting in severe chromosome missegregation, aneuploidy, and cell death (4, (9) (10) (11) (12) . CFI-402257 inhibited the activation of the SAC with an IC 50 value of 64 ± 5 nM as monitored in an assay in which the disappearance of histone H3 serine 10 phosphorylation was assessed in HCT116 human colon carcinoma cells treated with the spindle poison nocodazole (Fig. 1C) . This phosphorylation event in histone H3 is a posttranslational modification that identifies mitotic cells (prophase to anaphase), and is not a result of Mps1 activity. To examine the effect of CFI-402257 on the fidelity of chromosome segregation, HCT116 cells were treated with the inhibitor, and the number of chromosome segregation errors present in mitotic cells was determined by immunostaining for centromeres, α-tubulin to visualize the mitotic spindle, and DAPI. Treatment with 200 nM CFI-402257 caused a massive increase in chromosome missegregations relative to DMSO control cells ( Fig. 2A) .
SAC inactivation and gross chromosome segregation errors caused by CFI-402257 had a major impact on the cell-cycle progression and survival of human cancer cells. CFI-402257 induced a dose-dependent dysregulation of the cell cycle, resulting in an increase in the frequency of cells exhibiting an aneuploid DNA content (Fig. 2B ). Massive aneuploidy was observed with 100 nM CFI-402257, and significant polyploidy was not observed with CFI-402257 concentrations as high as 3,000 nM as a result of the potency and selectivity of the compound. The ability of CFI-402257 to cause aneuploidy in cancer cells was confirmed by metaphase chromosome spread assay (Fig. 2C ). CFI-402257-induced aneuploidy was accompanied by a progressive accumulation of apoptotic cells that were detectable as early as 16 h following treatment (Fig. 2D ). The effects described here for CFI-402257 are in accordance with cellular depletion of Mps1 protein or inhibition of Mps1 with other compounds (4, 9-12). Thus, CFI-402257 inhibits Mps1 in human cancer cells and modulates the physiological role of the kinase.
We evaluated the effect of CFI-402257 on growth inhibition (i.e., IC 50 ) in a panel of human cancer-derived cell lines covering various cancer histologies after 5 d. CFI-402257 exerted potent growth inhibitory activity across the vast majority of cell lines with a median IC 50 value of 15 nM (range, 1 to >1,500 nM; Fig. 3 and Table S2 ). Notably, no single gene mutation in several proteins relevant to oncogenesis (e.g., APC, BRAF, CDKN2A, PIK3CA, RAS and TP53; Sanger Institute Catalog Of Somatic Mutations In Cancer database, cancer.sanger.ac.uk/cosmic/) or cell doubling time was correlated with statistical significance with the resistance/sensitivity of the cell lines to CFI-402257.
Toxicity Studies of CFI-402257. The tolerability and pharmacokinetic properties of CFI-402257 were initially evaluated in mice. To determine a tolerable dose range for in vivo efficacy studies, mice were given CFI-402257 orally for 21 d, with doses ranging from 4.5 to 6.5 mg/kg. The upper dose level [i.e., maximum tolerated dose (MTD)] for once-daily (QD) administration of CFI-402257 was between 6 and 6.5 mg/kg, defined as the highest dose that did not cause >10% loss in body weight or induce overt toxicity (i.e., signs of ill health or abnormal behaviors, including hunched posture, poor grooming, urine stains, diarrhea, or dehydration) in accordance with institutional humane endpoint guidelines.
Comprehensive toxicologic evaluation of CFI-402257 administered to rats and dogs has been completed. In summary, dose-limiting toxicities were found to be reversible gastrointestinal effects and myelosuppression, which are consistent with the proposed mechanism of action of the molecule (Table S3 ). The toxicological profile of CFI-402257 supports its clinical development to determine its potential as an effective treatment in oncology.
In Vivo Characterization of the Anticancer Potential of CFI-402257. Pharmacokinetic parameters were determined by treating mice with single oral doses of CFI-402257 (Fig. S3) . Plasma was obtained at specified time points, and concentrations of CFI-402257 were determined by liquid chromatography (LC)-tandem MS (LC/MS/MS). CFI-402257 was absorbed rapidly after oral administration, and exposure [in terms of area under the curve (AUC) and maximum plasma concentrations (C max )] was dose-dependent and approximately dose-linear to 55 mg/kg. At the repeat-dose MTD of 6.5 mg/kg, the C max was 1,070 ng/mL and the AUC 0-24h was 3,170 ng·h/mL. The elimination t 1/2 ranged between 2 and 3 h. These data demonstrate that CFI-402257 has a favorable pharmacokinetic profile. CFI-402257 has demonstrated efficacy as a monotherapy in cancer cell line and patient-derived xenograft (PDX) models across various indications, and representative studies are described here. CFI-402257 given orally QD showed dose-dependent activity in mice with established tumors from xenografted MDA-MB-231 human TNBC cells [5 mg/kg CFI-402257, tumor growth inhibition (TGI) = 74%, P = 0.02; 6 mg/kg CFI-402257, TGI = 89%, P = 0.004; Fig. 4A ]. Similar results were obtained in tumors from xenografted MDA-MB-468 human TNBC cells in mice (5 mg/kg CFI-402257, TGI = 75%, P = 0.003; 6 mg/kg CFI-402257, TGI = 94%, P = 0.001; Fig. 4B) . CFI-402257 also demonstrated antitumor activity in a platinum-resistant PDX model of high-grade serous ovarian cancer (6.5 mg/kg CFI-402257, TGI = 61%, P = 0.04; 75 mg/kg carboplatin, TGI = 97%, P = 0.03; Fig. 4C ). Further, CFI-402257 was found to be similarly efficacious in a platinum-sensitive PDX model of high-grade serous ovarian cancer (Fig. 4D) . CFI-402257 was well-tolerated at the doses examined as measured by little to no decrease in body weight (<10% change) and normal behavior. Together, these results indicate that CFI-402257 can inhibit the growth of a range of tumor types and may be effective in a clinical setting.
To determine the pharmacodynamics of CFI-402257 in vivo, phospho-histone H3 serine 10-positive cells were counted in the MDA-MB-231 breast tumor xenografts treated with the daily dose MTD of 6 mg/kg for 3 d or a large acute dose of 35 mg/kg twice daily (BID) for five doses ( inhibitors, immunocompetent BALB/cJ mice were inoculated with syngeneic CT26 mouse colon carcinoma cells and then treated with CFI-402257 alone and in combination with an anti-PD-1 antibody (Fig. 6) . Tumors in the vehicle-treated control arm grew rapidly, and the average size was >1,500 mm 3 by day 11 of treatment. Although there was tumor growth delay in the anti-PD-1 antibody-and the CFI-402257-treated single-agent arms, there were no instances in which complete regression was observed. In the combination anti-PD-1 antibody and CFI-402257-treated arm, however, two of the eight tumors completely regressed. Very similar results were also seen in a duplicate experiment (Fig. S4) , again with complete regression (two of eight tumors) only seen in the combination arm. In the former experiment, the two animals in which complete regression had occurred were rechallenged by inoculation with CT26 cells on day 31. Tumors did not grow in either mouse, indicating that immunity to the CT26 cells had been generated.
Discussion
The primary function of the SAC is to prevent chromosome missegregation and the generation of aneuploid or polyploid cells. Thus, the SAC ensures healthy proliferation and precise division in cells, and targeting this checkpoint could provide new therapeutic opportunities for killing cancer cells. Differently from antimitotic/antitubulin therapy, which arrests cell proliferation, inactivation of the SAC would lead to an accelerated mitosis and the consequent generation of lethal genomic instability in cancer cells. The strong requirement for Mps1 for the SAC has made it a candidate for this therapeutic approach, and has generated intense interest in developing small-molecule inhibitors against this kinase (4, 9-12, 25, 26) .
We report here the functional characterization of CFI-402257, a potent and orally active inhibitor of Mps1 that has entered a phase I clinical trial (ClinicalTrials.gov ID: NCT02792465). CFI-402257 is highly selective toward Mps1 relative to other protein and lipid kinases, and did not inhibit several kinases that are known for their role in mitosis. CFI-402257 pharmacologically recapitulates previous findings obtained upon Mps1 deletion or with other Mps1-specific inhibitors (4, (9) (10) (11) (12) . Specifically, CFI-402257 treatment potently inhibited Mps1 kinase activity in cancer cells, and causes cancer cells to exit mitosis with missegregated chromosomes, which results in severe aneuploidy and finally cell death. Cancer cell line profiling demonstrated that CFI-402257 has broad and strong antiproliferative activity. Although cell lines with high and low sensitivity toward CFI-402257 treatment were identified, no single gene implicated via mutation in human cancer could be clearly correlated. This suggests that multiple genes and/or kinetochore-specific factors may determine the cellular sensitivity to Mps1 inhibitors. Further investigation is ongoing to identify candidate predictive biomarkers for CFI-402257 and to understand which particular class of malignancies might benefit from Mps1-targeted agents.
Mouse plasma concentration-time profiles indicate that, following oral administration of efficacious doses of CFI-402257 in mice, plasma levels of CFI-402257 were sustained and remained above the EC 50 value for half-maximal inhibition of cellular Mps1 autophosphorylation and the median growth-inhibition IC 50 value for greater than 12 h. Moreover, CFI-402257 monotherapy demonstrated dose-dependent antitumor activity. Analysis of xenograft tumors from mice treated with an efficacious dose of CFI-402257 showed pharmacodynamic effects consistent with inhibition of Mps1. Together, these results provide evidence that the antitumor activity of CFI-402257 results from its in vivo inhibition of Mps1.
Mps1 inhibitors BAY 1161909 (ClinicalTrials.gov ID: NCT02138812), BAY 1217389 (ClinicalTrials.gov ID: NCT02366949), and S 81694 (EudraCT no.: 2014-002023-10) are currently in phase I clinical trials. As has been presented for CFI-402257, these inhibitors have cellular on-target activity and have significant tumor growth-inhibitory activity in preclinical models (27, 28) . However, comparison of the reported pharmacological properties and preclinical data for these inhibitors reveals differences. CFI-402257 shows higher kinase selectivity compared with BAY 1161909, BAY 1217389, or S 81694. Although additional activities could provide enhanced efficacy in particular settings, they may also result in reduced tolerance. Specifically, the toxicities observed for this class of drug targets (i.e., myelosuppression and gastrointestinal disturbances) suggest that the balance between efficacy and tolerability may not be one that allows additional activities to contribute to an antitumor effect. These inhibitors have been evaluated by using different dosing schedules and routes of delivery. Daily oral dosing has been used for CFI-402257, intermittent oral dosing for BAY 1161909 and BAY 1217389, and intermittent i.v. dosing for S 81694. Notably, the preclinical studies for these inhibitors have shown that both daily and intermittent dosing schedules are efficacious and generally well-tolerated, giving confidence that an efficacious and tolerated schedule can be found in patients. Preclinical efficacy results for BAY 1161909 and BAY 1217389 showed moderate activity as monotherapies, but strong cooperativity with taxanes, and this combination has advanced to the clinic (discussed later). CFI-402257 and S 81694 showed single-agent activity in preclinical studies, and have entered clinical testing in monotherapy. The relative importance of these factors and other subtle differences between these drug candidates, and others that may emerge, as well as the genetic makeup of the tumor, will be established by ongoing clinical studies.
Mechanism-based combination strategies are being explored for Mps1 inhibitors in an effort to expand their therapeutic utility and delay the onset of resistance. Mps1 inhibitors are mitosis-promoting agents that, when used with antitubulin agents, which perturb proper chromosome alignment, are expected to increase chromosome segregation errors above the threshold required to kill cancer cells. In support of this hypothesis, Mps1 inhibitors have been shown to sensitize cancer cells to taxane treatment (29) , and this approach is being tested clinically (27) . Furthermore, the combination of Mps1 and cyclin-dependent kinase 4/6 inhibition has been investigated as a strategy to increase the therapeutic window for Mps1 inhibitors (30) . Cdk4/6 inhibitors trigger G1 cell cycle arrest in Rb1-competent cells, and thus might improve the tolerability and efficacy of Mps1 inhibitors. Early results support this hypothesis, and suggest that the combination may prove particularly effective in Rb1-dysregulated cancers. The rationale for another combination approach for Mps1 inhibitors may lie in the proteotoxic or metabolic stress caused by the chromosome imbalance in aneuploid cancer cells (31) . Here, treatment of cancer cells with Mps1 inhibitors that increase aneuploidy could synergize with ones that target the proteotoxic or metabolic stress induced by aneuploidy. Whether aneuploidy-induced stress pathway inhibitors might synergize with Mps1 inhibitors remains to be determined. Chemotherapy, targeted therapies, and radiotherapy can promote tumor immunity by inducing immunogenic cell death (32, 33) . Combinations of these cancer therapies with immune-checkpoint inhibitors are being explored to achieve additive or synergistic clinical activity. Here, we show that the combination of CFI-402257 and an anti-PD-1 antibody causes tumor regression and increases the survival in a murine colon cancer model. The reason for this response is likely complex and under investigation. One possible explanation may lie in the genomic instability and apoptosis in tumor cells caused by CFI-402257-induced Mps1 inhibition. These events might lead to the creation of new immunogenic epitopes, which are able to induce cytotoxic T lymphocyte activity against tumor cells. Further studies of immune-checkpoint inhibitors are merited to support their use in combination treatment with Mps1 inhibitors.
In summary, CFI-402257 is a potential small-molecule inhibitor for the treatment of cancer with a mechanism of action that is consistent with potent and selective inhibition of Mps1. CFI-402257 has been approved for human use by Health Canada, and a phase I clinical trial has been initiated.
Methods
Compounds and Plasmids. CFI-402257 was synthesized as described previously (23) . The hydrochloride or bisphosphate hemihydrate salt forms of CFI-402257 were used in all studies. Thymidine, nocodazole, and MG132 were obtained from Sigma. Rat IgG2a anti-PD-1 antibody (clone RMP1-14; cat. no. BE0146) and rat IgG2a isotype control (clone 2A3; cat. no. BE0089) were obtained from Bio X Cell. Carboplatin was obtained from Teva Canada. The expression construct encoding full-length human Mps1 was obtained from Origene.
Animals. C.B.-17 SCID and NSG mice were obtained from the animal colony at the Ontario Cancer Institute of the University Health Network (Toronto). CD-1 Nude mice were obtained from Charles River Laboratories. BALB/cJ mice were obtained from The Jackson Laboratory. Six-to eight-week-old female animals were used for the studies and were allowed unrestricted access to food and water. All animal procedures were approved by the institutional animal care and use committee of the University Health Network (Toronto).
Xenograft Tumor Growth. The PDXs were generated from platinum-resistant or platinum-sensitive high-grade serous ovarian cancers that were obtained from the University Health Network Tissue Bank with patient consent and research ethics board approval (protocol 06-0903T) (34) 
